Pacira BioSciences, Inc. (PCRX) |
| 23.22 -0.46 (-1.94%) 05-29 16:00 |
| Open: | 23.66 |
| High: | 23.97 |
| Low: | 23.17 |
| Volume: | 511,332 |
| Market Cap: | 913(M) |
| PE Ratio: | 178.62 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 27.13 |
| Resistance 1: | 25.13 |
| Pivot price: | 23.19 |
| Support 1: | 21.90 |
| Support 2: | 18.22 |
| 52w High: | 27.64 |
| 52w Low: | 18.8 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| EPS | 0.130 |
| Book Value | 16.630 |
| PEG Ratio | 11.21 |
| Gross Profit | 14.816 |
| Profit Margin (%) | 0.70 |
| Operating Margin (%) | 2.61 |
| Return on Assets (ttm) | 1.4 |
| Return on Equity (ttm) | 0.7 |
Fri, 29 May 2026
Pacira (PCRX): Glass Lewis Recommends Stockholder Votes - GuruFocus
Thu, 28 May 2026
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Thu, 28 May 2026
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees - markets.businessinsider.com
Thu, 28 May 2026
Pacira BioSciences, Inc. Receives Glass Lewis Endorsement for Director Nominees Ahead of 2026 Annual Meeting - Quiver Quantitative
Wed, 27 May 2026
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details - Yahoo Finance
Wed, 27 May 2026
Pacira (PCRX) Highlights Positive Study Outcomes on Exparel Usage - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |